122 related articles for article (PubMed ID: 1381394)
1. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells.
Finberg RW; White W; Nicholson-Weller A
J Immunol; 1992 Sep; 149(6):2055-60. PubMed ID: 1381394
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
Seya T; Kojima A; Hara T; Hazeki K; Sugita Y; Akedo H
Immunobiology; 1991 Sep; 183(1-2):115-24. PubMed ID: 1718846
[TBL] [Abstract][Full Text] [Related]
3. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
Bonavida B; Lebow LT; Bradley TP
J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
[TBL] [Abstract][Full Text] [Related]
5. MHC class I expression on tumor targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition.
Kaufman DS; Schoon RA; Leibson PJ
J Immunol; 1993 Feb; 150(4):1429-36. PubMed ID: 8432986
[TBL] [Abstract][Full Text] [Related]
6. T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules.
Schmidt RE; Caulfield JP; Michon J; Hein A; Kamada MM; MacDermott RP; Stevens RL; Ritz J
J Immunol; 1988 Feb; 140(3):991-1002. PubMed ID: 3276787
[TBL] [Abstract][Full Text] [Related]
7. Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells.
Roozemond RC; Bonavida B
J Immunol; 1985 Apr; 134(4):2209-14. PubMed ID: 3855929
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
9. Effect of altered membrane structure on NK cell-mediated cytotoxicity. II. Conversion of NK-resistant tumor cells into NK-sensitive targets upon fusion with liposomes containing NK-sensitive membranes.
Roozemond RC; van der Geer P; Bonavida B
J Immunol; 1986 May; 136(10):3921-9. PubMed ID: 3701064
[TBL] [Abstract][Full Text] [Related]
10. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.
Oshimi Y; Oda S; Honda Y; Nagata S; Miyazaki S
J Immunol; 1996 Oct; 157(7):2909-15. PubMed ID: 8816396
[TBL] [Abstract][Full Text] [Related]
12. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
13. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.
Nishimura M; Mitsunaga S; Akaza T; Mitomi Y; Tadokoro K; Juji T
Immunology; 1994 Sep; 83(1):75-80. PubMed ID: 7821970
[TBL] [Abstract][Full Text] [Related]
14. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
Perl A; Looney RJ; Ryan DH; Abraham GN
J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
[TBL] [Abstract][Full Text] [Related]
15. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
Katz JD; Mitsuyasu R; Gottlieb MS; Lebow LT; Bonavida B
J Immunol; 1987 Jul; 139(1):55-60. PubMed ID: 3584988
[TBL] [Abstract][Full Text] [Related]
17. Target cell directed NK inactivation. Concomitant loss of NK and antibody-dependent cellular cytotoxicity activities.
Abrams SI; Brahmi Z
J Immunol; 1988 Mar; 140(6):2090-5. PubMed ID: 3279127
[TBL] [Abstract][Full Text] [Related]
18. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
19. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
[TBL] [Abstract][Full Text] [Related]
20. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
